OcugenFRA:2H51 -1.06%20 Net Margin % is -1,250.98% as of Mar. 2026. GuruFocus rates FRA:2H51 with a GF Score™ of 20/100 and a GF Value™ of €0.69 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 938 Biotechnology companies, Ocugen ranks worse than 82.84% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Ocugen's Net Income for the
three
months ended in Mar. 2026 was €-16.59 Mil. Ocugen's Revenue for the
three
months ended in Mar. 2026 was €1.33 Mil. Therefore, Ocugen's net margin for the quarter that ended in Mar. 2026 was -1,250.98%.
The historical rank and industry rank for Ocugen's Net Margin % or its related term are showing as below:
FRA:2H51'
s Net Margin % Range Over the Past 10 Years
Min: -50748.84 Med: -1537.41 Max: -1045.03
Current: -1605.22
FRA:2H51's Net Margin % is ranked worse than 82.84% of 938
companies
in the Biotechnology industry
Industry Median: -88.09
vs FRA:2H51: -1605.22
Ocugen (FRA:2H51) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Ocugen Net Margin % Related Terms
Ocugen Net Margin % Historical Data
* Premium members only.
The historical data trend for Ocugen's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2H51 vs STRO, NGNE, CBIO: Net Margin % Comparison
For the Biotechnology subindustry, Ocugen's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocugen Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocugen's Net Margin % distribution charts can be found below:
* The bar in red indicates where Ocugen's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocugen (FRA:2H51) has a Net Margin % of -1,250.98% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Ocugen and its competitors. According to the industry distribution chart, Ocugen ranks #777 out of 938 companies in the Biotechnology industry, placing it in the top 82.8%.
Is Ocugen's Net Margin % too high?
Ocugen's current Net Margin % is -1,250.98%. Based on the distribution chart, Ocugen ranks #777 out of 938 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ocugen has a GF Score™ of 20/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ocugen's Net Margin % compare to STRO and NGNE?
According to the Biotechnology industry distribution chart, Ocugen ranks #777 out of 938 companies for Net Margin %. This places Ocugen in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Ocugen and its competitors. Ocugen's current Net Margin % is -1,250.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocugen stock overvalued right now?
Based on GuruFocus' analysis, Ocugen (FRA:2H51) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.69, compared to a current price of €1.31 — trading 89.9% above its estimated fair value. The current Net Margin % is -1,250.98%. Ocugen's overall GF Score™ is 20/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Ocugen (FRA:2H51), the current Net Margin % is -1,250.98% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ocugen (FRA:2H51) Overvalued in 2026?
Based on GuruFocus' analysis, Ocugen stock appears to be overvalued.
The current stock price of €1.31 is trading 89.9% above its estimated GF Value™ of €0.69.
GuruFocus considers Ocugen to be Significantly Overvalued.
Key valuation signals for FRA:2H51:
Net Margin %: -1,250.98%
GF Value™: €0.69 vs. price of €1.31 (89.9% above fair value)
No single metric tells the full story. See the FRA:2H51 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
20GF Score
Get the complete analysis for FRA:2H51
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2H51 has been successfully added to your 
